Pfizer in its $5.4 billion acquisition of Global Blood Therapeutics

On August 8, 2022, Pfizer Inc. and Global Blood Therapeutics, Inc. announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD).  Under the terms of the transaction, Pfizer will acquire all the outstanding shares of GBT for $68.50 per share in cash for a total enterprise value of approximately $5.4 billion.

Wachtell, Lipton, Rosen & Katz served as legal advisor to Pfizer.